Research Center, Policlinico di Monza Foundation, Via Pietro Micca 29, 13100, Vercelli, Italy.
Neurol Sci. 2017 Sep;38(9):1571-1577. doi: 10.1007/s10072-017-3002-x. Epub 2017 Jun 7.
The paper wants to be a tracking shot of the main recent acquisitions on the function and significance of microglia/macrophages in gliomas. The observations have been principally carried out on in vitro cultures and on tumor transplants in animals. Contrary to what is deduced from microglia in non-neoplastic pathologic conditions of central nervous system (CNS), most conclusions indicate that microglia acts favoring tumor proliferation through an immunosuppression induced by glioma cells. By immunohistochemistry, different microglia phenotypes are recognized in gliomas, from ramified microglia to frank macrophagic aspect. One wonders whether the functional conclusions drawn from many microglia studies, but not in conditions of human pathology, apply to all the phenotypes recognizable in them. It is difficult to verify in human pathology a prognostic significance of microglia. Only CD163-positive microglia/macrophages inversely correlate with glioma patients' survival, whereas the total number of microglia does not change with the malignancy grade.
本文旨在追踪最近关于小胶质细胞/巨噬细胞在神经胶质瘤中的功能和意义的主要研究进展。这些观察主要是在体外培养和动物肿瘤移植中进行的。与中枢神经系统(CNS)非肿瘤性病理条件下推断的小胶质细胞不同,大多数结论表明,小胶质细胞通过肿瘤细胞诱导的免疫抑制作用促进肿瘤增殖。通过免疫组织化学,在神经胶质瘤中可以识别出不同的小胶质细胞表型,从分枝状小胶质细胞到明显的巨噬细胞样形态。人们不禁要问,从许多小胶质细胞研究中得出的功能结论,但不是在人类病理学条件下,是否适用于所有可识别的表型。在人类病理学中,很难验证小胶质细胞的预后意义。只有 CD163 阳性小胶质细胞/巨噬细胞与神经胶质瘤患者的生存呈负相关,而小胶质细胞的总数并不随恶性程度的变化而变化。